Better Therapeutics- Tradeable Rights - March 2021 Gross Profit

The latest gross profit for MCADR is $-3.1M as of September 2023. That compares with $-550K in the prior-year period — down 464.1% year over year. That is below the sector sector average of $790M. Investors often review this figure alongside Better Therapeutics- Tradeable Rights - March 2021's historical trend and sector peers before judging valuation or financial health.

Over the past year, MCADR's gross profit moved from $-550K to $-3.1M — a 464.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Better Therapeutics- Tradeable Rights - March 2021's operating scale or balance-sheet position.

Against its sector companies, MCADR currently prints $-3.1M for gross profit, while the sector average sits near $790M. That is roughly 100.4% below the sector mean. Large gaps often invite a closer look at Better Therapeutics- Tradeable Rights - March 2021's growth, margins, and balance sheet.

A gross profit figure of $-3.1M for MCADR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $790M. Explore the charts below for those layers of context.

After noting MCADR's gross profit ($-3.1M), review year-over-year change from $-550K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.